Get the Daily Brief
Latest Biotech News
GSK Commits $30 Billion to U.S. Manufacturing and R&D Expansion
GlaxoSmithKline announced a $30 billion investment plan over five years enhancing drug production, discovery, and clinical trials in the United States. This move intensifies GSK’s focus on its...
AI Designs Functional Viruses to Kill Bacteria
Researchers at Stanford and the Arc Institute used artificial intelligence models trained on millions of bacteriophage genomes to design new viral genomes. Of 302 AI-generated genetic designs...
Colossal Biosciences Raises $120M to Advance De-Extinction Projects
Colossal Biosciences has expanded its Series C funding round with an additional $120 million, bringing total raised to over $555 million since inception. The Dallas-based company focuses on...
Lilly’s Oral GLP-1 Pill Outperforms Novo Nordisk’s in Diabetes Trial
Eli Lilly announced that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight reduction compared to Novo Nordisk’s oral Rybelsus in a...
Dualitas Therapeutics Launches with $65M to Develop Bispecific Antibodies for Immune Diseases
Dualitas Therapeutics emerged from stealth mode following a $65 million Series A financing co-led by Versant Ventures and Qiming Venture Partners USA. The Bay Area biotech aims to develop...
Alchemab Therapeutics Raises $32M to Propel Antibody Pipeline and Lilly Collaboration
UK-based Alchemab expanded its Series A financing round by $32 million, bringing the total to $114 million to advance its AI-driven antibody discovery platform. The funding will support...
Next-Gen Cancer Immunotherapy Platform: MIT’s Antibody-Bottlebrush Conjugates
Scientists at MIT developed antibody-bottlebrush conjugates (ABCs), a novel cancer therapy platform that vastly increases drug-to-antibody ratios compared to traditional antibody-drug conjugates...
New CRISPR-Based Tongue Swab Test Transforms Tuberculosis Screening
Tulane University researchers developed ActCRISPR-TB, an innovative assay integrating isothermal amplification and CRISPR-Cas12a in a single reaction to detect Mycobacterium tuberculosis DNA from...
Synthesize Bio Launches with $10M Seed to Accelerate AI-Driven Drug Discovery
Seattle-based Synthesize Bio announced its launch backed by a $10 million seed round led by Madrona, focusing on generative AI biological foundation models for improving drug discovery and design....
Novartis, Monte Rosa Boost Immune Drug Pipeline With $5.7B Molecular Glue Deal
Novartis has expanded its collaboration with Monte Rosa Therapeutics, committing up to $5.7 billion to develop molecular glue degraders targeting immune-mediated diseases. The deal includes an...
Lilly Outpaces Novo Nordisk in Oral GLP-1 Diabetes Trial; FDA Filing Pending
Eli Lilly reported that its oral GLP-1 candidate orforglipron surpassed Novo Nordisk’s Rybelsus in a Phase 3 diabetes trial, lowering HbA1c more and producing greater weight loss. The highest dose...
Atyr Pharma’s Lead Lung Drug Fails Phase 3 Trial, Shares Collapse
Biotech aTyr Pharma announced that its Phase 3 trial of efzofitimod failed to meet the primary endpoint of reducing steroid use in pulmonary sarcoidosis patients. The drug showed a modest,...
CSL Secures $117M Option to Acquire Dutch Blood Clotting Drug Developer VarmX
CSL Ltd. invested $117 million to acquire an exclusive option to purchase VarmX BV, a developer of VMX-C001, a Phase 3-ready drug targeting blood coagulation reversal in patients on Factor Xa...
Ollin Biosciences Launches with $100M, Targets Roche’s Eye Drug Market
Ophthalmologist Jason Ehrlich launched Ollin Biosciences with $100 million in funding to develop novel antibody therapeutics aimed at eye diseases. The company's lead bispecific antibody, OLN324,...
Regeneron Reports Positive Phase 3 Data for Rare Skeletal Disease Drug
Regeneron Pharmaceuticals announced a pivotal Phase 3 trial success for garetosmab, a drug for fibrodysplasia ossificans progressiva (FOP), an ultra-rare condition causing abnormal bone formation....
AI Advances Enable Cardiovascular Risk Prediction from Mammograms
Researchers at The George Institute for Global Health have developed a machine learning algorithm that analyzes routine mammograms to accurately predict cardiovascular disease (CVD) risk in women....
New CRISPR-Based Oral Test Promises Faster, Non-Invasive TB Detection
Tulane University researchers developed ActCRISPR-TB, a novel CRISPR-Cas12a assay capable of detecting Mycobacterium tuberculosis DNA from tongue swabs within an hour. The single-pot, isothermal...
Areteia Therapeutics’ Oral Asthma Drug Meets Primary Endpoint in Phase 3 Trial
Areteia Therapeutics reported positive Phase 3 results for dexpramipexole, an oral small molecule targeting eosinophilic asthma. The Exhale-4 trial met its primary endpoint, showing significant...
Novartis Expands Immunology Pipeline with Monte Rosa Molecular Glue Deal
Novartis has deepened its collaboration with Monte Rosa Therapeutics by agreeing on a new partnership worth up to $5.7 billion to develop multiple molecular glue degraders targeting...
aTyr Pharma’s Efzofitimod Fails Phase 3 Trial in Pulmonary Sarcoidosis
aTyr Pharma’s experimental drug efzofitimod did not meet its primary endpoint in a Phase 3 study aiming to reduce oral steroid use in patients with pulmonary sarcoidosis. Despite some promising...